(Yahoo! Finance) June 10, 2021 – VERU-100 formulated to address the clinical limitations of currently available androgen deprivation therapy. The Phase 2 clinical trial is expected to be completed by 2H calendar 2021.
Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer
by MM360 Staff | Jun 10, 2021 | Uncategorized | 0 comments